title: Placebo controlled continuation treatment with Hypericum extract WS 5570 after recovery from a mild or moderate depressive episode.
abstract: Patients suffering from an acute episode of mild to moderate major depression and who had been treated successfully with Hypericum perforatum extract WS 5570 in doses of 600 mg/day or 1200 mg/day or with placebo for 6 weeks in a multi-centre, double-blind, randomized clinical trial, were asked to take part in a continuation treatment. Those participants with a HAMD total score decrease > or =50% during acute treatment were eligible for 4 months of double-blind continuation treatment with the same dose regimen. In total, 69, 68 and 24 (WS 5570 600 mg/day, 1200 mg/day and placebo) patients entered continuation treatment. Both WS 5570 groups showed an additional slight decrease of the HAMD total score by 0.8 (600 mg WS 5570/day) and 0.4 (1200 mg WS 5570/day) points during treatment phase, while patients in the placebo group deteriorated by 2.1 points. The incidence of adverse events was low in all therapy groups.
authors: Department of Psychiatry and Psychotherapy, Medical University Vienna, Austria. sci-genpsy@meduniwien.ac.at
authors: Siegfried
authors: S
authors: Kasper
authors: Ion-Gheorge
authors: IG
authors: Anghelescu
authors: Armin
authors: A
authors: Szegedi
authors: Angelika
authors: A
authors: Dienel
authors: Meinhard
authors: M
authors: Kieser
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020902:Hypericum; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010919:Placebos; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D010936:Plant Extracts
references: Pharmacopsychiatry. 2001 May;34(3):96-103
references: 11434406
references: J Geriatr Psychiatry Neurol. 1994 Oct;7 Suppl 1:S12-4
references: 7857500
references: J Geriatr Psychiatry Neurol. 1994 Oct;7 Suppl 1:S9-11
references: 7857516
references: Fortschr Med Orig. 2001 Nov 29;119(3-4):119-28
references: 11789123
references: BMJ. 2005 Mar 5;330(7490):503
references: 15708844
references: Am J Psychiatry. 2002 Aug;159(8):1361-6
references: 12153829
references: Pharmacopsychiatry. 1997 Sep;30 Suppl 2:81-5
references: 9342765
references: Pharmacopsychiatry. 1998 Jun;31 Suppl 1:54-9
references: 9684948
references: J Clin Psychiatry. 1991 Feb;52 Suppl:12-6; discussion 17
references: 1995597
references: Biol Psychiatry. 1998 Sep 1;44(5):348-60
references: 9755357
references: Arch Gen Psychiatry. 1992 Oct;49(10):769-73
references: 1417428
references: Br J Psychiatry Suppl. 1994 Dec;(26):31-6
references: 7873135
references: BMC Med. 2006 Jun 23;4:14
references: 16796730
references: Pharmacopsychiatry. 2005 Mar;38(2):78-86
references: 15744631
references: Int Clin Psychopharmacol. 1998 Jul;13 Suppl 6:S23-6
references: 9728671
references: Br J Psychiatry. 2005 Feb;186:99-107
references: 15684231
references: Phytomedicine. 2005 Jan;12(1-2):148-57
references: 15693723
references: Phytomedicine. 1998 Dec;5(6):435-42
references: 23196026
references: Arch Gen Psychiatry. 1998 Dec;55(12):1128-32
references: 9862557
references: Pharmacopsychiatry. 2006 Nov;39(6):213-9
references: 17124643